

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 August 2024 (02.08.2024)



(10) International Publication Number
WO 2024/158973 A2

(51) International Patent Classification:
C12N 15/74 (2006.01) C12N 1/20 (2006.01)

(21) International Application Number:
PCT/US2024/012881

(22) International Filing Date:
25 January 2024 (25.01.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/481,499 25 January 2023 (25.01.2023) US
63/613,843 22 December 2023 (22.12.2023) US

(71) Applicant: **NOVEL BIOTECHNOLOGY INC.**
[CA/CA]; 81 Zenway Boulevard, Unit 3A, Vaughn, Ontario
L4H 0S5 (CA).

(72) Inventor; and

(71) Applicant: **WEINSTOCK, Matthew** [US/US]; 4012 SE
Sunrise Drive, Camas, Washington 98607 (US).


(72) Inventor: **KALLIVALAPPIL, Santhosh T.**; c/o Nov-
el Biotechnology Inc., 81 Zenway Boulevard, Unit 3A,
Vaughn, Ontario L4H 0S5 (CA).

(74) Agent: **WILSON, Khadija D.** et al.; c/o Greenberg Trau-
rig, LLP, One International Place Suite, 2000, Boston, Mass-
achusetts 02110 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: EXPRESSION SYSTEM FOR PRODUCT MANUFACTURING

FIG. 2



(57) Abstract: The present disclosure provides engineered bacterial cells having one or more genetic modifications that result in increased production of expression products, such as increased production of plasmids with reduced occurrence of plasmid concatemers or multimers. Also disclosed herein are expression systems for product manufacturing in media having reduced antibiotic concentration, as well as methods of making cells for use in the expression systems. The cells and expression systems increase the growth rate and production yields of biomolecules produced within the host bacterial host cells without the use of antibiotics, and can produce the product with little to no endotoxins present.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*